Technical Analysis for SVRA - Savara, Inc.

Grade Last Price % Change Price Change
grade C 9.55 0.84% 0.08
SVRA closed up 0.84 percent on Friday, September 22, 2017, on 6.08 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical SVRA trend table...

Date Alert Name Type % Chg
Sep 22 Volume Surge Other 0.00%
Sep 21 Stochastic Reached Overbought Other 0.84%
Sep 20 NR7 Range Contraction 8.03%
Sep 20 Calm After Storm Range Contraction 8.03%
Sep 18 Volume Surge Other 12.49%

Older signals for SVRA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Get Started for Free!
Basic chart:

Profile
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Is SVRA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Sep 21 Savara to Present at the Cantor Fitzgerald 2017 Global Healthcare Conference on September 27th
Sep 5 Savara to Present at the Rodman & Renshaw 19th Annual Global Investment Conference on September 11th
Aug 9 Savara Reports Second Quarter 2017 Financial Results and Provides Business Update
Jul 11 Positive Interim Results Of Aironite Phase 2 Study Presented At 4th Annual Drug Discovery And Development Symposium For Pulmonary Hypertension
Jun 20 Savara Set To Join Russell Microcap® Index
Jun 9 Savara Inc (SVRA) CEO Robert N Neville Bought $248,188 of Shares
Jun 7 Savara Announces Closing Of Public Offering Of Common Stock
Jun 5 Savara To Present At The Jefferies 2017 Global Healthcare Conference On June 9th
Jun 2 InPlay from Briefing.com
Jun 2 Savara Announces Pricing Of Public Offering Of Common Stock
See more SVRA news...
Indicators
Indicator Value
52 Week High 16.1
52 Week Low 4.6
Average Volume 86,130
200-Day Moving Average 7.2732
50-Day Moving Average 6.3165
20-Day Moving Average 7.1298
10-Day Moving Average 8.5717
Average True Range 0.6359
ADX 45.4
+DI 46.02
-DI: 9.76
Chandelier Exit (Long, 3 ATRs) 8.0923
Chandelier Exit (Short, 3 ATRs) 6.9777
Upper Bollinger Band 10.2984
Lower Bollinger Band 3.9612
Percent B (%b) 0.88
Bandwidth 0.888833
MACD Line 0.9559
MACD Signal Line 0.6886
MACD Histogram 0.2673